Regenxbio (RGNX) Begins Phase I Trial of RGX-314 Gene Therapy for Wet AMD – StreetInsider.com
|
Regenxbio (RGNX) Begins Phase I Trial of RGX-314 Gene Therapy for Wet AMD
StreetInsider.com REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that the first patient was dosed … |
